HansBiomed Corporation (042520) - Total Assets
Based on the latest financial reports, HansBiomed Corporation (042520) holds total assets worth ₩126.41 Billion KRW (≈ $85.66 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore HansBiomed Corporation cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
HansBiomed Corporation - Total Assets Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's total assets have evolved over time, based on quarterly financial data. See 042520 total equity for net asset value and shareholders' equity analysis.
HansBiomed Corporation - Asset Composition Analysis
Current Asset Composition (September 2025)
HansBiomed Corporation's total assets of ₩126.41 Billion consist of 44.4% current assets and 55.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.5% |
| Accounts Receivable | ₩16.65 Billion | 13.2% |
| Inventory | ₩28.83 Billion | 22.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩535.75 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of HansBiomed Corporation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HansBiomed Corporation's current assets represent 44.4% of total assets in 2025, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 8.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 22.8% of total assets.
HansBiomed Corporation Competitors by Total Assets
Key competitors of HansBiomed Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
HansBiomed Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.69 | 0.99 | 1.85 |
| Quick Ratio | 0.34 | 0.43 | 1.41 |
| Cash Ratio | 0.00 | 0.13 | 0.00 |
| Working Capital | ₩-24.96 Billion | ₩-385.31 Million | ₩36.19 Billion |
HansBiomed Corporation - Advanced Valuation Insights
This section examines the relationship between HansBiomed Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.49 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | ₩126.41 Billion |
| Market Capitalization | $163.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values HansBiomed Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: HansBiomed Corporation's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HansBiomed Corporation (2012–2025)
The table below shows the annual total assets of HansBiomed Corporation from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | ₩126.41 Billion ≈ $85.66 Million |
+3.85% |
| 2024-09-30 | ₩121.72 Billion ≈ $82.48 Million |
-0.53% |
| 2023-09-30 | ₩122.37 Billion ≈ $82.93 Million |
-7.08% |
| 2022-09-30 | ₩131.69 Billion ≈ $89.24 Million |
+1.73% |
| 2021-09-30 | ₩129.44 Billion ≈ $87.72 Million |
-1.79% |
| 2020-09-30 | ₩131.81 Billion ≈ $89.32 Million |
-1.71% |
| 2019-09-30 | ₩134.09 Billion ≈ $90.87 Million |
+46.08% |
| 2018-09-30 | ₩91.80 Billion ≈ $62.21 Million |
+14.47% |
| 2017-09-30 | ₩80.19 Billion ≈ $54.34 Million |
+23.91% |
| 2016-09-30 | ₩64.72 Billion ≈ $43.86 Million |
+24.19% |
| 2015-09-30 | ₩52.11 Billion ≈ $35.32 Million |
+17.52% |
| 2014-09-30 | ₩44.34 Billion ≈ $30.05 Million |
+32.91% |
| 2013-09-30 | ₩33.36 Billion ≈ $22.61 Million |
+23.33% |
| 2012-09-30 | ₩27.05 Billion ≈ $18.33 Million |
-- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more